P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

Схожі ресурси

• Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
  за авторством: Bhayat, F, та інші
  Опубліковано: (2017)
• Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
  за авторством: Bhayat, F, та інші
  Опубліковано: (2017)
• Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
  за авторством: Travis, S, та інші
  Опубліковано: (2018)
• The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
  за авторством: Cohen, R, та інші
  Опубліковано: (2019)
• Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
  за авторством: Card, T, та інші
  Опубліковано: (2019)